**Abstracts**

**EPV277/#126**  A CROSS-SECTIONAL, NON-INTERVENTIONAL, MULTICENTRIC STUDY TO DETERMINE THE PREVALENCE OF HOMOLOGOUS RECOMBINATION DEFICIENCY AMONG WOMEN WITH NEWLY DIAGNOSED, HIGH-GRADE, SEROUS OR ENDOMETROID OVARIAN CANCER

1 C Malaga*, 2 M Mokhtar, 3 H Azim, 4 A Typlidou, 4 C-H Wu, 5 LS Yeh, 6 W S Liu, 7 W F Cheng, 8 A Chao, 9 AstraZeneca, Medical, San Jose – Costa Rica, UK; 10 Kas El Ainy School of Medicine – Cairo University, Medical Oncology, Cairo, Egypt; 11 N N. Blokhin National Medical Research Center of Oncology, Medical Oncology, Moscow, Russia; 12 Kaohsiung Chang Gung Memorial Hospital, Gynecology, Kaohsiung City, Taiwan; 13 China Medical University Hospital, Gynecology, Taichung, Taiwan; 14 Kaohsiung Veterans General Hospital, Gynecology, Kaohsiung City, Taiwan; 15 National Taiwan University Hospital, Gynecology, Taipei City, Taiwan; 16 Chang Gung Memorial Hospital-Linkou, Gynecology, Taoyuan City, Taiwan

10.1136/ijgc-2021-IGCS.348

**Objectives** Background Homologous recombination deficiency (HRD) is common in women with newly diagnosed high-grade serous ovarian and other morphologically related cancers. Exploiting the prevalence of HRD positive status can help optimize the use of targeted therapies in these patients and improve survival. Due to limited statistics, the study is aimed to determine global as well as country-specific (Egypt, Lebanon, Malaysia, Russia, Singapore, Taiwan, Saudi Arabia, Turkey, and United Arab Emirates) data on the prevalence of HRD positive patients using locally developed tests and commercial kits.

**Methods** Method Study design and population: This cross-sectional, non-interventional, multicentre observational study will enroll a minimum of 405 women (≥ 18 years) with high-grade serous or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer having histopathology report and formalin-fixed paraffin-embedded (FFPE) tumour tissue block (s). FFPE tissue blocks will be used for HRD status and BRCA mutation testing. Objective: Primary endpoints include prevalence of patients with positive HRD status. Secondary endpoints include 1) Region- and country-specific prevalence of the patients with a) positive HRD status, b) positive tBRCA1m/tBRCA2m; 2) risk factors associated with these patients. Exploratory endpoints include clinical characteristics of overall patient population and by geographical regions. Statistical analysis: Analyses will be performed using full analysis set (FAS). Logistic regression analysis will be used to identify the potential risk factors.

**Results** Trail in progress.

**Conclusions** Importance The study will generate reliable evidence on prevalence of HRD positive patients and help health care professionals to understand the clinical and genetic characteristic of the disease in various countries guiding optimal treatment.

**EPV279/#351**  EPIK-O/ENGOT-OV61: A PHASE 3, RANDOMIZED STUDY OF ALPELISIB + OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR -REFRACTORY, HIGH-GRADE SEROUS OVARIAN CANCER

1 P Konstantinopoulou*, 2 A González-Martín, 3 F Cruz, 4 M Friedlander, 5 R Glasspool, 6 O Lorusso, 7 C Marsh, 8 B Monk, 9 J-W Kim, 10 A Ladarius, 11 F Prete, 12 H Han, 13 U Matulonis, 14 Dana-Farber Cancer Institute, Medical Oncology, Boston, USA; 15 Clínica Universidad de Navarra, Department of Medical Oncology, Madrid, Spain; 16 Instituto Brasileiro de Controle do Cancer, Clinical Research Center, Sao Paulo, Brazil; 17 University of New South Wales, Medical Oncology, Sydney, Australia; 18 Beatson West of Scotland Cancer Centre and University of Glasgow, Clinical Trials Unit, Glasgow, UK; 19 Fondazione Policlinico Universistario A Gemelli IRCCS, Gynecology Oncology Unit, Milano, Italy; 20 Medizinische Universität Innsbruck, Department of Obstetrics and Gynecology, Innsbruck, Austria; 21 University of Arizona, College of Medicine, Phoenix, USA; 22 Seoul National University, Obstetrics and Gynecology, Seoul, Korea, Republic of; 23 Novartis Pharmaceuticals Corporation, Global Medical Affairs, Oncology, East Hanover, USA

10.1136/ijgc-2021-IGCS.350

**Objectives** High-grade serous ovarian cancer (HGSOCC) represents most epithelial ovarian cancers. Whilst initially responding to platinum-based therapy, ~75% of patients develop resistance, conferring poor prognosis. Homologous recombination repair proficiency is associated with platinum resistance and limited response to PARP inhibitors. PI3K pathway inhibition downregulates BRCA expression, abrogating homologous recombination repair proficiency, and may lead to (re)sensitization to PARP inhibitors. As alpelisib (PI3K inhibitor) + olaparib (PARP inhibitor) demonstrated preliminary synergism in platinum-resistant/refractory, BRCA-wild-type, recurrent HGSOCC in a phase 1b study, the EPIK-O study is further evaluating this combination.

**EPV278/#248**  A RANDOMIZED CONTROLLED PHASE II CLINICAL TRIAL OF APATINIB PLUS CHEMOTHERAPY IN THE FIRST-LINE(1L) TREATMENT OF IVB STAGE, RECURRENT OR PERSISTENT CERVICAL CANCER

Y Zhou, Y Jiang, M Zheng*, Sun Yat-sen University Cancer Center, Gynaecology Department, Guangzhou, China

10.1136/ijgc-2021-IGCS.349

**Objectives** This study evaluates the efficacy and safety of apatinib combined with chemotherapy in cervical cancer.

**Methods** In this open-label phase II study, eligible patients were randomized(1:1) to receive treatment: Arm A) oral apatinib 375 mg once daily + intravenous paclitaxel (P) and cisplatin (DDP) or carboplatin (carb); Arm B) intravenous P and DDP or carb. Chemotherapy was administered for 4–6 cycles followed by apatinib. The primary endpoint was PFS assessed by RECIST1.1, and secondary endpoints included OS, ORR, DCR, DO, and safety/tolerability.

**Results** 61 patients were randomized to Arm A (n = 31) and Arm B (n = 30). Until March 30, 2021, the median follow-up was 10.7 months (range 1.73–32.23). Compared with patients in Arm B, patients in Arm A showed a higher PFS (13.6 vs. 5.2 months, HR, 0.455; 95% CI 0.239–0.865; P = 0.014), ORR (58.10% vs. 23.3%), and DCR (80.60% vs. 53.3%). Treatment-related AEs (TRAEs) occurred in 87% (A) and 40% (B); Grade ≥3 TRAEs occurred in 77% (A) and 30% (B), respectively. The most commonly reported grade ≥3 AEs were hematologic in nature (eg, neutropenia) and consistent with known chemotherapy AEs. Serious TRAEs were reported in 8 patients (22.6% [A]; 3.3% [B]); TRAE leading to death was reported in 1 patient in Arm A.

**Conclusions** As 1L treatment of IVB stage, recurrent or persistent cervical cancer, the addition of apatinib to chemotherapy significantly improved PFS and showed a higher ORR and DCR than chemotherapy alone. No new safety issues were identified with the addition of apatinib to chemotherapy.